Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax: 2010-2024

Historic Long-Term Deferred Tax for Vanda Pharmaceuticals (VNDA) over the last 7 years, with Dec 2024 value amounting to $81.4 million.

  • Vanda Pharmaceuticals' Long-Term Deferred Tax rose 29.88% to $103.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year increase of 29.88%. This contributed to the annual value of $81.4 million for FY2024, which is 8.59% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Long-Term Deferred Tax of $81.4 million as of FY2024, which was up 8.59% from $75.0 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $81.5 million for FY2020, and its period low was $74.0 million during FY2022.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $75.0 million (2023), whereas its average is $76.8 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Long-Term Deferred Tax declined by 8.14% in 2021, and later increased by 8.59% in 2024.
  • Vanda Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $81.5 million in 2020, then declined by 8.14% to $74.9 million in 2021, then decreased by 1.12% to $74.0 million in 2022, then rose by 1.30% to $75.0 million in 2023, then rose by 8.59% to $81.4 million in 2024.